Comorbidities in clinical cohorts of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
Eur Respir RevSep 9, 2026 (epub)
Marcus C H Leong, Seema Green, Mingkun Guan et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined the prevalence and impact of comorbidities in 606,398 patients with idiopathic pulmonary fibrosis (IPF). The study found that systemic hypertension had a pooled prevalence of 39%, while lung cancer was linked to increased mortality. The analysis included 251 studies and highlighted the need for personalized care in IPF management.
Key findings
- Systemic hypertension had a pooled prevalence of 39% (95% CI 34-44%) among patients with IPF.
- Lung cancer was consistently associated with increased short-term and long-term mortality in IPF patients.
- Dyslipidaemia and gastro-oesophageal reflux disease had prevalence rates of 30% and 27%, respectively.
Why it matters
Understanding the prevalence of comorbidities in IPF patients is crucial for clinicians, as these conditions can significantly influence treatment decisions and patient outcomes. Personalized management strategies may improve care for this complex patient population.